3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide CAS#: 1001917-37-8

ChemicalBook > Product Catalog > Biochemical Engineering > Inhibitors > protein tyrosine kinase > 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide

3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide

Basic information Safety Supplier Related

3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide Basic information

Product Name:

3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide

Synonyms:

3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide
MK-8033
1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide
3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinyLMethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridin
CS-2738
MK 8033;MK8033
CS-1167
100853

CAS:

1001917-37-8

MF:

C25H21N5O3S

MW:

471.53

Mol File:

1001917-37-8.mol

Less

3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide Chemical Properties

Boiling point:: 761.0±70.0 °C(Predicted)
Density: 1.39
storage temp.: Store at -20°C
solubility: Soluble in DMSO
pka: 8.93±0.40(Predicted)
form: Powder
color: Light yellow to yellow

Less

3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide Usage And Synthesis

Uses

MK 8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor and is used in the treatment of cancer.

in vivo

MK-8033 (Compound 11r, oral administration, 3-100 mg/kg, twice daily for 21 days) inhibits tumor growth in GTL-16 c-Met amplified gastric tumor xenografts^[1].
MK-8033 exhibits moderate clearance (t_1/2: 0.8 h for rats, 3.1 h for dog) and favorable bioavailability (35% for rats, 33% for dog)^[1].

Animal Model:	Human GTL-16 c-Met amplified gastric tumor xenografts^[1]
Dosage:	3, 10, 30, and 100 mg/kg
Administration:	Oral administration, twice daily for 21 days
Result:	Resulted in 22, 18, 57, and 86% tumor growth inhibition at 3, 10, 30, and 100 mg/kg, respectively. Inhibited c-Met (Y1349) phosphorylation.

IC 50

Ron: 7 nM (IC₅₀)

3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamideSupplier

Shanghai Boyle Chemical Co., Ltd.

Tel
Email: sales@boylechem.com

Chembest Research Laboratories Limited

Tel: +86-21-20908456
Email: sales@BioChemBest.com

ChemShuttle, Inc.

Tel: 0510-83588313-811 18800520310
Email: sales@chemshuttle.com

NCE Biomedical Co.,Ltd.

Tel: 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988

Haoyuan Chemexpress Co., Ltd.

Tel: 021-58950125
Email: info@chemexpress.com

Less

3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide(1001917-37-8)Related Product Information